OUTPACE

What this means for you

Not registered yet, but its 17 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99007123

Mark type

Stylized text

Filed

17 Jan 2025

Attorney of record

Sydney R. Jensen

Goods and services

• Class 005 — Pharmaceuticals: Therapeutics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cell therapies, in the nature of modified cells, engineered cells, therapeutic agents, and their delivery agents, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biopharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biologics in the nature of cells for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics in the nature of viral vectors for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; cells for medical or clinical purposes; viral or non-viral delivery vectors, namely, delivery agents for treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorder, and genetic disorders; pharmaceutical preparations for targeted cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for cellular therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; gene therapy products, namely, genetically engineered cells, cell components, molecules, proteins and protein complexes; therapeutic preparations, namely, therapeutic antigens for medical purposes and antibodies for medical purposes; engineered cells for medical use; bioengineered cells for medical use; biological preparations for use in cell engineering platforms cultures for medical purposes; biological preparations for use in protein design platforms for medical purposes; biological preparations designed by computational protein platforms for medical purposes; biological preparations designed by AI-powered protein design platforms for medical purposes; pharmaceutical preparations developed with a computational protein design platform for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations developed with AI-powered protein design platforms for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;

Owner

• Outpace Bio, Inc., Seattle, WA, US

Prosecution history

• 05 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
• 05 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 05 Feb 2026 — EXAMINERS AMENDMENT E-MAILED
• 05 Feb 2026 — EXAMINERS AMENDMENT -WRITTEN
• 07 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 06 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 06 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 06 Oct 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 06 Oct 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 07 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 07 Jul 2025 — NON-FINAL ACTION E-MAILED
• 07 Jul 2025 — NON-FINAL ACTION WRITTEN
• 27 Jun 2025 — ASSIGNED TO EXAMINER
• 17 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 17 Jan 2025 — NEW APPLICATION ENTERED